

Two Canadian Researchers Receive Sanofi-CARO Award

□

From left to right: Recipients of the Sanofi-CARO Award - Dr. Robert Bristow, Senior Scientist, Princess Margaret Cancer Centre (University Health Network) and Dr. Eric Vigneault, Radio- Oncologist, Centre hospitalier universitaire de Québec (CHUQ).

July 22, 2015, Ottawa, Ont. – The Canadian Association of Radiation Oncology (CARO) is pleased to announce that Dr. Robert Bristow and Dr. Eric Vigneault have been selected to receive the Sanofi-CARO Award and have each been awarded \$24,000 to continue their research in prostate cancer therapies. The unrestricted research grant was made possible through funding by Sanofi Canada.

“We are excited to be able to offer Dr. Bristow and Dr. Vigneault the opportunity to further advance science and develop new treatments for prostate cancer through the new Sanofi-CARO Award,” claims Dr. Ross Halperin, President, CARO.

“Sanofi Canada has a long history in supporting and offering innovative research. We recognize the important work of radiation oncology clinicians and researchers in developing new treatments for prostate cancer. We need to work together to improve patient health outcomes and find solutions so that patients have access to the right treatment options that help them live healthier and longer lives,” explains Franca Mancino, Vice-President, Medical and Regulatory Affairs, at Sanofi Canada.

Sanofi-CARO Award recipients:

Dr. Robert Bristow, Senior Scientist, at the Princess Margaret Cancer Centre (University Health Network), has been awarded a research grant of \$24,000 for his work in characterizing the influence of prostate cancer genome instability and hypoxia on radiation therapy outcome.

Dr. Eric Vigneault, Radio- Oncologist, at the Centre hospitalier universitaire de Québec (CHUQ) has been granted \$24,000 to further his evaluation of the risk of lung cancer in patients with iodine 125 seed migration to lung after permanent prostate implant.

Their research projects were chosen for funding on the basis of their high scientific merit, feasibility and relevance to Canadian Radiation Oncology. The funds awarded must be spent within Canada.

Advances in therapy offer hope to patients and their families. By supporting such projects, it confirms a commitment to ongoing research and innovation to find solutions that improve quality of life and even prolong it.

About the Canadian Association of Radiation Oncology

Canadian Association of Radiation Oncology (CARO) – Association canadienne de radio-oncologie (ACRO) is a not-for-profit association with the mandate to represent and support its membership nationally and internationally, through the promotion of high standards of patient care in the practice of radiation oncology, support of excellence in professional standards, and the promotion of radiation oncology research and education. CARO is a partner with other disciplines in seeking to improve outcomes for cancer patients, and provides a consultative authority to oncology related agencies, academic institutions, and to the public in all matters pertaining to radiotherapy and oncology in Canada. For further information: www.caro-acro.ca

About Sanofi – www.sanofi.ca

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi entities in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (cosmeceuticals, over-the-counter products and specialty care), Genzyme (rare diseases) and Merial (animal health). Together they employ close to 1,700 people. In 2014 Sanofi companies invested \$130.5 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow Sanofi Canada on Twitter [@SanofiCanada](https://twitter.com/SanofiCanada) and on YouTube youtube.com/user/sanoficanada

For further information:

CARO

Narma Yogan

Senior Association Coordinator

905-415-3917

caro-acro@secretariatcentral.com

Sanofi Canada

Catherine Rose Cunningham

Manager, Corporate and Brand Communications

514-956-6120

Catherine.cunningham@sanofi.com
